Black Titan Corp (NASDAQ:BTTC) Short Interest Update

Black Titan Corp (NASDAQ:BTTCGet Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 21,671 shares, a decrease of 94.5% from the August 15th total of 395,561 shares. Based on an average trading volume of 3,966,225 shares, the short-interest ratio is currently 0.0 days. Currently, 0.4% of the shares of the company are sold short.

Hedge Funds Weigh In On Black Titan

Hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC acquired a new stake in Black Titan during the 4th quarter valued at approximately $840,000. HRT Financial LP acquired a new stake in shares of Black Titan in the fourth quarter worth $28,000. Renaissance Technologies LLC purchased a new position in shares of Black Titan during the fourth quarter worth $26,000. Finally, Marex Group plc purchased a new position in shares of Black Titan during the fourth quarter worth $84,000.

Black Titan Stock Performance

BTTC traded down $0.02 on Thursday, reaching $0.37. 129,544 shares of the stock were exchanged, compared to its average volume of 3,556,627. The company’s 50-day moving average price is $0.67 and its 200 day moving average price is $1.02. Black Titan has a fifty-two week low of $0.35 and a fifty-two week high of $39.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.62 and a quick ratio of 4.62. The firm has a market capitalization of $3.95 million, a PE ratio of -0.12 and a beta of 1.17.

Black Titan (NASDAQ:BTTCGet Free Report) last posted its quarterly earnings results on Friday, June 12th. The company reported ($0.22) earnings per share for the quarter. The business had revenue of $0.59 million during the quarter.

Black Titan Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Further Reading

Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.